ITP
CYTK icon

Iron Triangle Partners’s Cytokinetics CYTK Stock Holding History

Iron Triangle Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300,000
Closed -$21M – 31
2024
Q1 		$21M Buy
+300,000
New +$23.2M 2.15% 23

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Iron Triangle Partners's CYTK Position: Q2 2024 in Review

Iron Triangle Partners sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 300,000 shares — an estimated $21M sold.

Iron Triangle Partners first reported a position in CYTK in Q1 2024 and held it in 1 quarter. The position peaked at $21M in Q1 2024. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • Iron Triangle Partners reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • Iron Triangle Partners sold 300,000 Cytokinetics shares in Q2 2024, an estimated $21M.
  • Iron Triangle Partners first reported a position in Cytokinetics in Q1 2024 and held it in 1 quarter.
  • Iron Triangle Partners's Cytokinetics position peaked at $21M in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Iron Triangle Partners's 13F filing for Q2 2024, filed 14 Aug 2024.